NCT00732056View on ClinicalTrials.gov

A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

September 30, 2011

Study Completion Date

March 31, 2012

Conditions

Breast Cancer

Interventions

DRUG

GRN163L

25% dose escalation infused over 2 hours weekly

Trial Locations (2)

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

60426

Ingalls Memorial Hospital, Harvey

Sponsors

Lead Sponsor

Geron Corporation

All Listed Sponsors

lead

Geron Corporation

INDUSTRY